Relationship between FDG PET finding and oncologic gene mutation in hepatic/cholangic/pancreatic tumors

Relationship between FDG PET finding and oncologic gene mutation in hepatic/cholangic/pancreatic tumors - FDG PET and oncologic mutation in hepatic/cholangic/pancreatic tumors

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000015737

Enrollment

Registered

2014-12-04

Start date

2014-12-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant tumor of liver, bile duct system and pancreas.

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient who were performed resection of hepatic/chorangic and pancreatic cancer and also performed FDG PET imaging during July 2010 and Sept 2014.

Exclusion criteria

Exclusion criteria: 1: Patient with FDG PET image quality which is too poor to interpret. 2: The cases which the cancer tissue is not available.

Design outcomes

Primary

Measure	Time frame
Clinical diagnosis, finding of FDG PET imaging and measured uptake of FDG. Pathological parameters measured on cancer sample such as invasiveness. Expression glucose transporter, hexokinese and G-6-Pase on cancer tissue. Expression and mutation of cancer related genes such as p53 on cancer tissue.	—

Countries

Japan

Contacts

Public ContactTakashi Kudo

Atomic bomb disease institute, Nagasaki University Department of Radioisotope medicine

tkudo123@nagasaki-u.ac.jp095-819-7101

Outcome results